OJEMDA’s Performance Powers Day One’s Best Quarter—2025 Revenue Guidance Lifted
Day One Biopharmaceuticals (NASDAQ: DAWN) just posted its third quarter results, and the numbers tell a story of steady execution and growing momentum. With net product revenue from OJEMDA reaching $38.5 million in Q3—a 15% jump from the prior quarter—Day One is not only accelerating sales but raising its full-year revenue guidance for OJEMDA to $145–$150 million. Year-to-date OJEMDA revenue hit $102.6 million, up an impressive 89% over 2024’s full-year tally.
Surging Prescription Growth and Positive Demand Signals
Key metrics from the third quarter underline broadening adoption among prescribers:
- OJEMDA’s quarterly prescriptions (TRx) climbed to 1,256, up 18% from Q2.
- New patient starts increased 19% quarter-over-quarter, fueled by ongoing clinical data readouts.
- Clinical validation is set to expand, with three-year data from the pivotal FIREFLY-1 trial due for release in November at the Society for Neuro-Oncology.
Robust Financials Backing Clinical Progress
The company ended Q3 with $451.6 million in cash, cash equivalents, and short-term investments, providing a solid runway to support its advancing clinical pipeline and commercial plans. OJEMDA’s expanding role as a second-line standard of care for pediatric low-grade glioma (pLGG) continues to drive growth.
| Key Q3 2025 Financials | Q3 2025 | Q3 2024 |
|---|---|---|
| OJEMDA Net Product Revenue | $38.5M | $20.1M |
| Total Revenues | $39.80M | $93.76M* |
| Research & Development Expenses | $31.42M | $33.56M |
| Selling, General & Administrative Expenses | $28.15M | $28.97M |
| Net (Loss)/Income | ($19.73M) | $37.04M |
| Cash & Equivalents | $451.6M | $531.7M** |
*Q3 2024 includes $73.7M in one-time license revenue
**Dec 31, 2024
Pipeline and Clinical Developments Signal Longer-Term Upside
Clinical momentum continues as the FIREFLY-2 Phase 3 trial in first-line pLGG nears full enrollment in early 2026. Day One is also advancing dose escalation for DAY301, its next-generation antibody drug conjugate. Notably, tovorafenib (OJEMDA) was recently recognized as a recommended therapy in NCCN guidelines for adult BRAF-altered glioma, broadening its clinical profile.
Strategic Hires and Financial Discipline Underpin Execution
The company welcomed industry veteran Heather Adkins Huet, PhD, as Chief Scientific Officer, underscoring Day One’s commitment to scaling innovation and driving long-term pipeline value. Operating expenses were managed efficiently, with both R&D and SG&A expenses modestly lower year-over-year. Despite a net loss for the quarter (reflecting expected R&D investment), the healthy cash position is a critical asset.
Takeaway: Accelerating Growth, Clear Catalysts Ahead
Investors watching Day One can take note: robust revenue growth, expanded clinical milestones, and upcoming data presentations set up the next phase of potential upside. With new clinical data and ongoing trials in the pipeline, the coming quarters may offer more catalysts to sustain Day One’s trajectory. The company’s strong cash balance ensures it can continue executing without immediate funding pressures. Keep an eye on the upcoming FIREFLY-1 trial results and how they may further define OJEMDA’s position in pediatric and adult glioma therapy.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI